Literature DB >> 11532968

A novel cardioprotective role of RhoA: new signaling mechanism for adenosine.

J E Lee1, G Bokoch, B T Liang.   

Abstract

Adenosine exerts a potent cardioprotective effect that is mediated by adenosine A1 and A3 receptors. The signaling pathways activated by the A1 and A3 receptors are distinct and involve selective coupling to phospholipases C and D, respectively. The objective of our study was to elucidate the signaling mechanism that mediates the coupling of each receptor to its respective phospholipase and to test the role of RhoA as a novel mediator leading from adenosine receptors to cardioprotection. C3 transferase and dominant negative RhoA (RhoAT19N) blocked the A3 receptor-mediated phospholipase D activation and cardioprotection but had no effect on A1 receptor-mediated phospholipase C activation or cardioprotection. In contrast, pertussis toxin treatment caused a greater inhibition of the diacylglycerol accumulation induced by the A1 agonist than by the A3 agonist, and it completely abrogated the A1 agonist-mediated cardioprotection. Thus, adenosine A1 and A3 receptors are linked to different G-proteins. The A3 receptor is coupled via RhoA to activate phospholipase D in exerting its cardioprotective effect, whereas the A1 receptor is linked via Gi to phospholipase C to produce cardioprotective responses. The present study identifies a novel role for RhoA and further suggests its importance in regulating cardiac cellular function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11532968     DOI: 10.1096/fj.01-0212com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  12 in total

Review 1.  Cardiac purinergic signalling in health and disease.

Authors:  Geoffrey Burnstock; Amir Pelleg
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

2.  Orthogonal activation of the reengineered A3 adenosine receptor (neoceptor) using tailored nucleoside agonists.

Authors:  Zhan-Guo Gao; Heng T Duong; Tatiana Sonina; Soo-Kyung Kim; Philippe Van Rompaey; Serge Van Calenbergh; Liaman Mamedova; Hea Ok Kim; Myong Jung Kim; Ae Yil Kim; Bruce T Liang; Lak Shin Jeong; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2006-05-04       Impact factor: 7.446

3.  Neuropeptide Y increases 4-aminopyridine-sensitive transient outward potassium current in rat ventricular myocytes.

Authors:  M P Heredia; M Fernández-Velasco; G Benito; C Delgado
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

4.  Modulation of cardiac sarcoplasmic reticulum calcium release by aenosine: a protein kinase C- dependent pathway.

Authors:  Sandra Ghelardoni; Sabina Frascarelli; Vittoria Carnicelli; Simonetta Ronca-Testoni; Riccardo Zucchi
Journal:  Mol Cell Biochem       Date:  2006-04-01       Impact factor: 3.396

5.  Gene dosage-dependent effects of cardiac-specific overexpression of the A3 adenosine receptor.

Authors:  Richard G Black; Yiru Guo; Zhi-Dong Ge; Sidney S Murphree; Sumanth D Prabhu; W Keith Jones; Roberto Bolli; John A Auchampach
Journal:  Circ Res       Date:  2002-07-26       Impact factor: 17.367

6.  A3 adenosine and CB1 receptors activate a PKC-sensitive Cl- current in human nonpigmented ciliary epithelial cells via a G beta gamma-coupled MAPK signaling pathway.

Authors:  Chanjuan Shi; Anna Szczesniak; Lucy Mao; Christine Jollimore; Miguel Coca-Prados; Orlando Hung; Melanie E M Kelly
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

7.  A mammalian Rho-specific guanine-nucleotide exchange factor (p164-RhoGEF) without a pleckstrin homology domain.

Authors:  Ulrich Rümenapp; Andrea Freichel-Blomquist; Burkhard Wittinghofer; Karl H Jakobs; Thomas Wieland
Journal:  Biochem J       Date:  2002-09-15       Impact factor: 3.857

8.  Characterization of ERK1/2 signalling pathways induced by adenosine receptor subtypes in newborn rat cardiomyocytes.

Authors:  Renée Germack; John M Dickenson
Journal:  Br J Pharmacol       Date:  2004-01       Impact factor: 8.739

Review 9.  Identification of A3 adenosine receptor agonists as novel non-narcotic analgesics.

Authors:  K Janes; A M Symons-Liguori; K A Jacobson; D Salvemini
Journal:  Br J Pharmacol       Date:  2016-03-06       Impact factor: 8.739

10.  A3 adenosine receptor agonist prevents the development of paclitaxel-induced neuropathic pain by modulating spinal glial-restricted redox-dependent signaling pathways.

Authors:  Kali Janes; Emanuela Esposito; Timothy Doyle; Salvatore Cuzzocrea; Dillip K Tosh; Kenneth A Jacobson; Daniela Salvemini
Journal:  Pain       Date:  2014-09-19       Impact factor: 6.961

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.